Compare BTMD & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTMD | ENTX |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.4M | 62.6M |
| IPO Year | 2021 | 2015 |
| Metric | BTMD | ENTX |
|---|---|---|
| Price | $2.22 | $1.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $2.83 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 303.3K | 162.6K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 722.22 | N/A |
| EPS | ★ 0.74 | 0.25 |
| Revenue | ★ $192,219,000.00 | $42,000.00 |
| Revenue This Year | $2.03 | N/A |
| Revenue Next Year | $6.58 | N/A |
| P/E Ratio | ★ $3.03 | $4.88 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.27 | $0.91 |
| 52 Week High | $4.75 | $3.22 |
| Indicator | BTMD | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 69.22 | 47.32 |
| Support Level | $2.02 | $0.96 |
| Resistance Level | $2.79 | $1.61 |
| Average True Range (ATR) | 0.15 | 0.12 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 85.39 | 32.14 |
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.